Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

ClinicalTrials.gov ID: NCT03361956

Public ClinicalTrials.gov record NCT03361956. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection

Study identification

NCT ID
NCT03361956
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Janssen Sciences Ireland UC
Industry
Enrollment
232 participants

Conditions and interventions

Conditions

Interventions

  • JNJ-56136379 Drug
  • Placebo Drug
  • NA (ETV or TDF) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 12, 2018
Primary completion
Sep 4, 2019
Completion
Aug 12, 2020
Last update posted
Nov 16, 2022

2018 – 2020

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
The Office of Franco Felizarta, MD Bakersfield California 93301
Orlando Immunology Center Orlando Florida 32803
Rush University Medical Center Chicago Illinois 60612
Tulane Medical Center (TMC) New Orleans Louisiana 70112
I.D. Care, Inc. Hillsborough New Jersey 08844
NYU Hepatology Associates New York New York 10016
UPMC Center For Liver Diseases Pittsburgh Pennsylvania 15213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03361956, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03361956 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →